Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

Abstract

Background Extremity rhabdomyosarcomas do not always show satisfactory outcomes. We analyzed data from 643 patients treated in 14 studies conducted by European and North American groups between 1983 and 2004 to identify factors predictive of outcome. Procedure Clinical factors, including age; histology; site of primary (hand and foot vs. other); size; invasiveness (T stage); nodal involvement (N stage); and treatment factors, including post-surgical group; chemotherapy type and duration; radiotherapy; and treatment (before or after 1995); were evaluated for impact on overall survival (OS). Results 5-year OS were 67% (se 1.8). Multivariate analysis showed that lower OS correlated with age >3 years, T2 and N1 stage, incomplete initial surgery, treatment before 1995, and European cooperative group treatment. Patients with gross residual disease after initial incomplete resection/biopsy had similar outcomes in both continental groups. The better global survival of patients treated in American studies was accounted for by differences in outcome in the subset of those with grossly resected tumors (OS 86% [se 3] for COG patients vs. 68% [se 4] for European patients (P = 0.004)). When excluding chemotherapy duration from the model, analysis in this subset of patients showed that cooperative group (P = 0.001), site (P = 0.001), and T stage (P = 0.05) were all significant. However, after adding duration of chemotherapy (≥ 27 weeks) to the model, only primary site remained significant (P = 0.006). Conclusion This meta-analysis confirms the role of many established prognostic factors but identifies for the first time that chemotherapy duration may have an impact on outcome in patients with grossly resected tumors.

Soft tissue sarcoma nomograms and their incorporation into practice

“…Treatment consists of multimodal therapy including chemotherapy and surgery with or without radiotherapy. A recent meta‐analysis of patients with RMS of the extremity treated within 14 studies reported a 5‐year OS rate of 67% …”

An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy

“…European and North American Groups have compared their experience in a series of workshops. The better EFS obtained in COG protocols in some groups of patients including RMS localized in parameningeal or extremity primary sites could be explained by more systematic use of local control measures, and especially radiotherapy. In fact, European groups tried to limit the use of radiotherapy in their trials with the goal of identifying patients who could avoid radiotherapy in an attempt to reduce side effects.…”

A home run for rhabdomyosarcoma after 30 years: What now?

“…Different protocols developed over the years have gradually reduced the total duration of treatments from the original 2 years without apparently impairing the results, but analyses on particular subgroups of patients would suggest a better outcome for patients treated for longer. 28 On the other hand, the better outcome achieved with the maintenance therapy may relate to the drugs involved, i.e., vinorelbine and/or low-dose cyclophosphamide. Their combined effect may elicit an anti-angiogenic mechanism, killing tumor cells resistant to the standard therapy.…”